{
    "clinical_study": {
        "@rank": "53724", 
        "arm_group": [
            {
                "arm_group_label": "Sequence Group A", 
                "arm_group_type": "Experimental", 
                "description": "200 mg Veliparib"
            }, 
            {
                "arm_group_label": "Sequence Group B", 
                "arm_group_type": "Experimental", 
                "description": "400 mg Veliparib"
            }, 
            {
                "arm_group_label": "Sequence Group C", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized Phase 1 study to evaluate the effects of Veliparib on cardiac\n      repolarization in patients with solid tumors who's cancer has recurred or is no longer\n      responding to current treatment."
        }, 
        "brief_title": "A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Ovarian Cancer", 
            "Colon Cancer", 
            "Lung Cancer", 
            "Gastric Cancer", 
            "Solid Tumors"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Colonic Neoplasms", 
                "Lung Neoplasms", 
                "Stomach Neoplasms", 
                "Ovarian Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed solid malignancy that is metastatic or unresectable for which standard\n             curative measures or other therapy that may provide clinical benefit do not exist or\n             are no longer effective.\n\n          -  Subjects with brain metastases must have clinically controlled neurologic symptoms.\n\n          -  Subject is able to swallow and retain oral  medications and does not have\n             uncontrolled emesis.\n\n          -  Subject has adequate bone marrow, renal and hepatic function per local laboratory\n             reference ranges.\n\n        Exclusion Criteria:\n\n          -  Uncorrected serum potassium, serum magnesium, serum calcium or free thyroxin (FT4)\n             and thyroid stimulating hormone (TSH) outside of normal reference ranges, or grade 2\n             hyponatremia or hypernatremia.\n\n          -  Subject has severe ECG morphologic abnormalities that make QTc evaluation difficult.\n\n          -  Subject has a history of cardiac conduction abnormalities.\n\n          -  Subject has a significant history of cardiovascular disease.\n\n          -  Subject has received any anti-cancer therapies 21 days prior to the first dose of\n             study drug, or has recovered to no better than a grade 2 or higher clinically\n             significant adverse effect(s)/toxicity(s) of the previous therapy.\n\n          -  Use of drugs with a known risk for QT prolongation and Torsades de Pointes within 7\n             days prior to the first study dose.\n\n          -  Use of tobacco or nicotine-containing products within 12 hours prior to the first\n             study dose."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02009631", 
            "org_study_id": "M12-020", 
            "secondary_id": "2013-002028-18"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence Group A", 
                    "Sequence Group B"
                ], 
                "intervention_name": "Veliparib (ABT-888)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sequence Group C", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Solid Tumors", 
            "Ovarian Cancer", 
            "Colon Cancer", 
            "Lung Cancer", 
            "Breast Cancer", 
            "Gastric Cancer"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }, 
                    "name": "Site Reference ID/Investigator# 116015"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116015", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Site Reference ID/Investigator# 116016"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116016", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Bend", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53095"
                    }, 
                    "name": "Site Reference ID/Investigator# 39966"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 39966", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningn", 
                        "country": "Netherlands", 
                        "zip": "9713 GZ"
                    }, 
                    "name": "Site Reference ID/Investigator# 117320"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 117320", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6229 HX"
                    }, 
                    "name": "Site Reference ID/Investigator# 117336"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 117336", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Site Reference ID/Investigator# 117517"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 117517", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Netherlands", 
                "Spain"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors", 
        "overall_contact": {
            "email": "diane.medina@abbvie.com", 
            "last_name": "Diane  M Medina, BA", 
            "phone": "847-935-3868"
        }, 
        "overall_contact_backup": {
            "email": "olivia.olivares@abbvie.com", 
            "last_name": "Olivia  G Olivares, MS", 
            "phone": "847-937-9121"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Stacie   Shepherd, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To evaluate the effect of Veliparib on corrected QT interval calculated by Fridericia's formula (QTcF)", 
            "safety_issue": "Yes", 
            "time_frame": "Electrocardiograms (ECGs) will be done at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 in triplicate, 1 time point on Day 2 of Periods 1, 2, and 3 and 1 time point on Day 3 of Period 3."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02009631"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic sampling maximum observed plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be drawn at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 and 1 time point on Day 2 of Periods 1, 2, and 3."
            }, 
            {
                "measure": "Pharmacokinetic sampling - time to maximum observed plasma concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be drawn at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 and 1 time point on Day 2 of Periods 1, 2, and 3."
            }, 
            {
                "measure": "Pharmacokinetic sampling - the area under the plasma concentration-time curve (AUC) from time 0-24 hours (AUC 0-24)", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be drawn at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 and 1 time point on Day 2 of Periods 1, 2, and 3."
            }, 
            {
                "measure": "The number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after last dose of study drug."
            }, 
            {
                "description": "Blood pressure, heart rate and temperature.", 
                "measure": "Vital Signs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after last dose of study drug."
            }, 
            {
                "description": "Hematology, chemistry, urinalysis", 
                "measure": "Clinical Laboratory Tests", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after last dose of study drug."
            }, 
            {
                "description": "A computerized tomography scan will be done at screening to document tumor size.", 
                "measure": "Tumor Assessment", 
                "safety_issue": "Yes", 
                "time_frame": "Screening"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}